Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Onkologia w Praktyce Klinicznej - Edukacja
MENU
Na skróty Ahead of print Zdeponuj artykuł Nagroda imienia Profesora Krzysztofa Krzemienieckiego Zalecenia postępowania diagnostyczno-terapeutycznego

dostęp otwarty

Tom 7, Nr 6 (2021)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2021-10-25
Pokaż PDF Pobierz plik PDF
Pobierz cytowanie

Leczenie chorych na zaawansowanego raka jelita grubego z mutacją w genie BRAFV600E

Maciej Krzakowski1, Beata Jagielska2, Tomasz Kubiatowski34, Barbara Radecka56, Maria Sąsiadek7, Bartosz Wasąg89, Piotr Wysocki10
Onkol Prakt Klin Edu 2021;7(6):347-360.
Afiliacje
  1. Klinika Nowotworów Płuca i Klatki Piersiowej, Narodowy Instytut Onkologii im. M. Skłodowskiej-Curie — Państwowy Instytut Badawczy w Warszawie
  2. Szpital Grochowski im. dr med. Rafała Masztaka, Warszawa
  3. Klinika Onkologii i Immunoonkologii z Oddziałem Dziennym Terapii Onkologicznej, Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie
  4. Klinika Onkologii i Chorób Piersi CMKP w Warszawie
  5. Klinika Onkologii, Instytut Nauk Medycznych, Uniwersytet Opolski w Opolu
  6. Opolskie Centrum Onkologii im. Prof. Tadeusza Koszarowskiego
  7. Katedra i Zakład Genetyki, Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu
  8. Katedra i Zakład Biologii i Genetyki Medycznej, Gdański Uniwersytet Medyczny
  9. Laboratorium Genetyki Klinicznej, Uniwersyteckie Centrum Kliniczne w Gdańsku
  10. Katedra i Klinika Onkologii, Uniwersytet Jagielloński — Collegium Medicum w Krakowie

dostęp otwarty

Tom 7, Nr 6 (2021)
STANOWISKO EKSPERTÓW (EXPERTS' OPINION)
Opublikowany online: 2021-10-25

Streszczenie

Postęp w zakresie rokowania chorych na raka jelita grubego jest między innymi związany z wprowadzaniem nowych metod systemowego leczenia ukierunkowanego molekularnie. Przykładem jest leczenie ukierunkowane chorych z mutacją BRAFV600E. Obecne stanowisko ekspertów zostało przygotowane w celu przedstawienia uwarunkowań genetycznych i diagnostycznych oraz możliwych do wykorzystania metod leczenia chorych na zaawansowanego raka jelita grubego z mutacją w genie BRAFV600E.

Streszczenie

Postęp w zakresie rokowania chorych na raka jelita grubego jest między innymi związany z wprowadzaniem nowych metod systemowego leczenia ukierunkowanego molekularnie. Przykładem jest leczenie ukierunkowane chorych z mutacją BRAFV600E. Obecne stanowisko ekspertów zostało przygotowane w celu przedstawienia uwarunkowań genetycznych i diagnostycznych oraz możliwych do wykorzystania metod leczenia chorych na zaawansowanego raka jelita grubego z mutacją w genie BRAFV600E.

Pełny tekst:

Pokaż PDF Pobierz plik PDF
Pobierz cytowanie

Słowa kluczowe

rak jelita grubego; zaawansowane stadium choroby; mutacja w genie BRAF; leczenie systemowe

Informacje o artykule
Tytuł

Leczenie chorych na zaawansowanego raka jelita grubego z mutacją w genie BRAFV600E

Czasopismo

Onkologia w Praktyce Klinicznej - Edukacja

Numer

Tom 7, Nr 6 (2021)

Typ artykułu

Wytyczne / stanowisko ekspertów

Strony

347-360

Opublikowany online

2021-10-25

Wyświetlenia strony

3255

Wyświetlenia/pobrania artykułu

544

Rekord bibliograficzny

Onkol Prakt Klin Edu 2021;7(6):347-360.

Słowa kluczowe

rak jelita grubego
zaawansowane stadium choroby
mutacja w genie BRAF
leczenie systemowe

Autorzy

Maciej Krzakowski
Beata Jagielska
Tomasz Kubiatowski
Barbara Radecka
Maria Sąsiadek
Bartosz Wasąg
Piotr Wysocki

Referencje (87)
  1. Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes. Oncogene. 2004; 23(38): 6445–6470.
    CrossRefPubMed
  2. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol. 2005; 23(2): 276–292.
    CrossRefPubMed
  3. Stjepanovic N, Moreira L, Carneiro F, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019; 30(10): 1558–1571.
    CrossRefPubMed
  4. McCartan D, Chatterjee S. Hereditary and familial cancer. Surgery (Oxford). 2018; 36(3): 145–150.
    CrossRef
  5. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11): 1350–1356.
    CrossRefPubMed
  6. Inamura K. Colorectal Cancers: An Update on Their Molecular Pathology. Cancers (Basel). 2018; 10(1).
    CrossRefPubMed
  7. Tie J, Desai J. Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies. Target Oncol. 2015; 10(2): 179–188.
    CrossRefPubMed
  8. NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/default.aspx (21.03.2020).
  9. Sveen A, Kopetz S, Lothe RA. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol. 2020; 17(1): 11–32.
    CrossRefPubMed
  10. Siddiqui AD, Piperdi B. KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol. 2010; 17(4): 1168–1176.
    CrossRefPubMed
  11. Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020; 5(1): 22.
    CrossRefPubMed
  12. Jones J, Renfro L, Al-Shamsi H, et al. Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol. 2017; 35(23): 2624–2630.
    CrossRef
  13. Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011; 117(20): 4623–4632.
    CrossRefPubMed
  14. Morris V, Overman MJ, Jiang ZQ, et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014; 13(3): 164–171.
    CrossRefPubMed
  15. van Krieken JH, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 2008; 453(5): 417–431.
    CrossRefPubMed
  16. Dijkstra JR, Heideman DAM, Meijer GA, et al. KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance. Virchows Arch. 2013; 462(1): 39–46.
    CrossRefPubMed
  17. Tsiatis AC, Norris-Kirby A, Rich RG, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn. 2010; 12(4): 425–432.
    CrossRefPubMed
  18. Tol J, Dijkstra JR, Vink-Börger ME, et al. High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med. 2010; 14(8): 2122–2131.
    CrossRefPubMed
  19. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27(8): 1386–1422.
    CrossRefPubMed
  20. Ebi H, Corcoran RB, Singh A, et al. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest. 2011; 121(11): 4311–4321.
    CrossRefPubMed
  21. Dienstmann R, Connor K, Byrne AT, et al. COLOSSUS Consortium. Precision Therapy in RAS Mutant Colorectal Cancer. Gastroenterology. 2020; 158(4): 806–811.
    CrossRefPubMed
  22. Margonis GA, Buettner S, Andreatos N, et al. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. JAMA Surg. 2018; 153(7): e180996.
    CrossRefPubMed
  23. Ma H, Brosens LAA, Offerhaus GJ, et al. Pathology and genetics of hereditary colorectal cancer. Pathology. 2018; 50(1): 49–59.
    CrossRefPubMed
  24. Praca zbiorowa. Optymalizacja diagnostyki patomorfologicznej i molekularnej oraz leczenia raka płuca ICD10-C34. 2020.
  25. Praca zbiorowa. Wpływ zmiany finansowania badan diagnostycznych genetycznych na dostępność do terapii innowacyjnych. 2020.
  26. EQA colon 2017.
  27. French AJ, Sargent DJ, Burgart LJ, et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res. 2008; 14(11): 3408–3415.
    CrossRefPubMed
  28. Kalady MF, Dejulius KL, Sanchez JA, et al. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum. 2012; 55(2): 128–133.
    CrossRefPubMed
  29. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009; 58(1): 90–96.
    CrossRefPubMed
  30. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005; 65(14): 6063–6069.
    CrossRefPubMed
  31. Chen D, Huang JF, Liu K, et al. BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One. 2014; 9(3): e90607.
    CrossRefPubMed
  32. Ogino S, Nosho K, Kirkner GJ, et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol. 2009; 27(9): 1477–1484.
    CrossRefPubMed
  33. Zarkavelis G, Boussios S, Papadaki A, et al. Current and future biomarkers in colorectal cancer. Ann Gastroenterol. 2017; 30(6): 613–621.
    CrossRefPubMed
  34. Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol. 2010; 21(12): 2396–2402.
    CrossRefPubMed
  35. Nakayama I, Hirota T, Shinozaki E. Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. Cancers (Basel). 2020; 12(11).
    CrossRefPubMed
  36. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010; 28(3): 466–474.
    CrossRefPubMed
  37. Ashktorab H, Ahuja S, Kannan L, et al. A meta-analysis of MSI frequency and race in colorectal cancer. Oncotarget. 2016; 7(23): 34546–34557.
    CrossRefPubMed
  38. Phipps AI, Buchanan DD, Makar KW, et al. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2012; 21(10): 1792–1798.
    CrossRefPubMed
  39. Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015; 148(1): 77–87.e2.
    CrossRefPubMed
  40. Bläker H, Alwers E, Arnold A, et al. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage. Clin Gastroenterol Hepatol. 2019; 17(3): 455–462.e6.
    CrossRefPubMed
  41. Taieb J, Le Malicot K, Shi Q, et al. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. J Natl Cancer Inst. 2017; 109(5).
    CrossRefPubMed
  42. Sinicrope FA, Shi Q, Allegra CJ, et al. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Oncol. 2017; 3(4): 472–480.
    CrossRefPubMed
  43. Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012; 18(3): 890–900.
    CrossRefPubMed
  44. Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012; 18(23): 6531–6541.
    CrossRefPubMed
  45. Schirripa M, Bergamo F, Cremolini C, et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer. 2015; 112(12): 1921–1928.
    CrossRefPubMed
  46. Kubota N, Taniguchi F, Nyuya A, et al. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. J Hepatobiliary Pancreat Sci. 2013; 20(2): 223–233.
    CrossRefPubMed
  47. Teng HW, Huang YC, Lin JK, et al. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol. 2012; 106(2): 123–129.
    CrossRefPubMed
  48. Johnson B, Jin Z, Truty MJ, et al. Impact of Metastasectomy in the Multimodality Approach for V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. Oncologist. 2018; 23(1): 128–134.
    CrossRefPubMed
  49. Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014; 20(20): 5322–5330.
    CrossRefPubMed
  50. Morris V, Overman MJ, Jiang ZQ, et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014; 13(3): 164–171.
    CrossRefPubMed
  51. Loupakis F, Cremolini C, Salvatore L, et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer. 2014; 50(1): 57–63.
    CrossRefPubMed
  52. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015; 16(13): 1306–1315.
    CrossRefPubMed
  53. Cremolini C, Antoniotti C, Rossini D, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treat- ment of patients with metastatic colorectal cancer (TRIBE2): a multi- centre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020; 21(4): 497–507.
  54. Cremolini C, Antoniotti C, Stein A, et al. FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable metastatic colorectal cancer (mCRC): A meta-analysis of individual patient data (IPD) from five randomized trials. J Clin Oncol. 2020; 38(15_suppl): 4015–4015.
    CrossRef
  55. Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005; 97(13): 981–989.
    CrossRefPubMed
  56. Price TJ, Hardingham JE, Lee CK, et al. Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. J Clin Oncol. 2011; 29(19): 2675–2682.
    CrossRefPubMed
  57. Wirapati P, Pomella V, Vandenbosch B, et al. Velour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity. J Clin Oncol. 2017; 35(15_suppl): 3538–3538.
    CrossRef
  58. Yoshino T, Obermannova R, Bodoky G, et al. Are BRAF mutated metastatic colorectal cancer (mCRC) tumors more responsive to VEGFR-2 blockage? Analysis of patient outcomes by RAS/RAF mutation status in the RAISE study—A global, randomized, double-blind, phase III study. J Clin Oncol. 2018; 36(4_suppl): 622–622.
    CrossRef
  59. Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014; 25(7): 1346–1355.
    CrossRefPubMed
  60. Seymour MT, Brown SR, Middleton G, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 2013; 14(8): 749–759.
    CrossRefPubMed
  61. Bokemeyer C, Van Cutsem E, Rougier P, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 2012; 48(10): 1466–1475.
    CrossRefPubMed
  62. Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2015; 51(5): 587–594.
    CrossRefPubMed
  63. Rowland A, Dias MM, Wiese MD, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015; 112(12): 1888–1894.
    CrossRefPubMed
  64. Yoshino T, Arnold D, Taniguchi H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018; 29(1): 44–70.
    CrossRefPubMed
  65. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Colon Cancer. Version 2. 2021.
  66. Stintzing S, Heinrich K, Tougeron D, et al. Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116). J Clin Oncol. 2021; 39(15_suppl): 3502–3502.
    CrossRef
  67. Yang H, Higgins B, Kolinsky K, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res. 2012; 72(3): 779–789.
    CrossRefPubMed
  68. Kopetz S, Desai J, Chan E, et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol. 2015; 33(34): 4032–4038.
    CrossRefPubMed
  69. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012; 483(7387): 100–103.
    CrossRefPubMed
  70. Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012; 2(3): 227–235.
    CrossRefPubMed
  71. Grothey A, Tabernero J, Taieb J, et al. LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer. Ann Oncol. 2020; 31: S242–S243.
    CrossRef
  72. ClinicalTrials.gov Identifier: NCT 04607421.
  73. Seppälä TT, Böhm JP, Friman M, et al. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br J Cancer. 2015; 112(12): 1966–1975.
    CrossRefPubMed
  74. Parsons MT, Buchanan DD, Thompson B, et al. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet. 2012; 49(3): 151–157.
    CrossRefPubMed
  75. Lochhead P, Kuchiba A, Imamura Yu, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013; 105(15): 1151–1156.
    CrossRefPubMed
  76. Saridaki Z, Souglakos J, Georgoulias V. Prognostic and predictive significance of MSI in stages II/III colon cancer. World J Gastroenterol. 2014; 20(22): 6809–6814.
    CrossRefPubMed
  77. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017; 18(9): 1182–1191.
    CrossRefPubMed
  78. Overman MJ, Lonardi S, Wong KaY, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018; 36(8): 773–779.
    CrossRefPubMed
  79. André T, Lonardi S, Wong K, et al. SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol. 2021; 32: S213–S214.
    CrossRef
  80. André T, Shiu KK, Kim TW, et al. KEYNOTE-177 Investigators. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020; 383(23): 2207–2218.
    CrossRefPubMed
  81. Nordlinger B, Sorbye H, Glimelius B, et al. EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK, Arbeitsgruppe Lebermetastasen und–tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013; 14(12): 1208–1215.
    CrossRefPubMed
  82. Yaeger R, Cercek A, Chou JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. 2014; 120(15): 2316–2324.
    CrossRefPubMed
  83. Corcoran RB, Atreya CE, Falchook GS, et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015; 33(34): 4023–4031.
    CrossRefPubMed
  84. Kopetz S, Desai J, Chan E, et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol. 2015; 33(34): 4032–4038.
    CrossRefPubMed
  85. Kopetz S, Grothey A, Cutsem EV, et al. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). J Clin Oncol. 2020; 38(15_suppl): 4001–4001.
    CrossRef
  86. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer. N Engl J Med. 2019; 381(17): 1632–1643.
    CrossRefPubMed
  87. Kopetz S, Grothey A, Cutsem EV, et al. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). J Clin Oncol. 2020; 38(4_suppl): 8–8.
    CrossRef

Regulamin

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

 

Wydawcą serwisu jest  VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl